AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 20.67 |
Market Cap | 13.73B |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | 0.98 |
PE Ratio (ttm) | 22.06 |
Forward PE | n/a |
Analyst | Buy |
Ask | 20.71 |
Volume | 794,560 |
Avg. Volume (20D) | 1,242,703 |
Open | 22.00 |
Previous Close | 21.72 |
Day's Range | 21.59 - 22.08 |
52-Week Range | 19.85 - 31.88 |
Beta | undefined |
About GMAB
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esoph...
Analyst Forecast
According to 7 analyst ratings, the average rating for GMAB stock is "Buy." The 12-month stock price forecast is $49, which is an increase of 126.64% from the latest price.
Next Earnings Release
Analysts project revenue of $886.73M, reflecting a 31.36% YoY growth and earnings per share of 0.39, making a 8.33% increase YoY.